Literature DB >> 25728134

Emerging influenza viruses and the prospect of a universal influenza virus vaccine.

Florian Krammer1.   

Abstract

Influenza viruses cause annual seasonal epidemics and pandemics at irregular intervals. Several cases of human infections with avian and swine influenza viruses have been detected recently, warranting enhanced surveillance and the development of more effective countermeasures to address the pandemic potential of these viruses. The most effective countermeasure against influenza virus infection is the use of prophylactic vaccines. However, vaccines that are currently in use for seasonal influenza viruses have to be re-formulated and re-administered in a cumbersome process every year due to the antigenic drift of the virus. Furthermore, current seasonal vaccines are ineffective against novel pandemic strains. This paper reviews zoonotic influenza viruses with pandemic potential and technological advances towards better vaccines that induce broad and long lasting protection from influenza virus infection. Recent efforts have focused on the development of broadly protective/universal influenza virus vaccines that can provide immunity against drifted seasonal influenza virus strains but also against potential pandemic viruses.
Copyright © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Avian influenza; Heterosubtypic immunity; Pandemic influenza; Universal influenza virus vaccine; Zoonotic influenza

Mesh:

Substances:

Year:  2015        PMID: 25728134     DOI: 10.1002/biot.201400393

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  31 in total

Review 1.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

Review 2.  Progress in developing virus-like particle influenza vaccines.

Authors:  Fu-Shi Quan; Young-Tae Lee; Ki-Hye Kim; Min-Chul Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2016-05-05       Impact factor: 5.217

3.  Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.

Authors:  Teddy John Wohlbold; Veronika Chromikova; Gene S Tan; Philip Meade; Fatima Amanat; Phillip Comella; Ariana Hirsh; Florian Krammer
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

4.  Avian and Human Seasonal Influenza Hemagglutinin Proteins Elicit CD4 T Cell Responses That Are Comparable in Epitope Abundance and Diversity.

Authors:  Anthony DiPiazza; Katherine Richards; Nicholas Poulton; Andrea J Sant
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

Review 5.  Development of a Universal Influenza Vaccine.

Authors:  Leonardo D Estrada; Stacey Schultz-Cherry
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

6.  Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Irina Margine; Gene S Tan; Ariana Hirsh; Florian Krammer
Journal:  Vaccine       Date:  2015-05-28       Impact factor: 3.641

Review 7.  Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Authors:  Taia T Wang; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

8.  Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.

Authors:  Attapon Kamlangdee; Brock Kingstad-Bakke; Jorge E Osorio
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

9.  Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.

Authors:  Felix Broecker; Sean T H Liu; Weina Sun; Florian Krammer; Viviana Simon; Peter Palese
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

10.  Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.

Authors:  Raffael Nachbagauer; David Shore; Hua Yang; Scott K Johnson; Jon D Gabbard; S Mark Tompkins; Jens Wrammert; Patrick C Wilson; James Stevens; Rafi Ahmed; Florian Krammer; Ali H Ellebedy
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.